As with the cancer types of each organ, different types of prostate cancer can be encountered in terms of aggressiveness according to the pathological degree and stage. As a result of this staging, a patient-specific risk ratio will arise.
Patients with prostate cancer are usually encountered in the early stages and treated with local treatment before it poses a life-threatening risk. Pathological examination will be re-evaluated after surgical treatments in this patient group. According to these results, patients will come to their 3-month outpatient clinic controls and will be evaluated for PSA test and general condition. In cases where the patient is under oncological control, there will be no need for any treatment other than follow-up in this way. Compared to other cancer types, it is extremely pleasing that the low-stage disease in prostate cancer does not affect the patient's life expectancy.
In cases such as an increase in the PSA test after the surgery, a stage jump in the pathology result, the presence of tumors above certain rates in the lymph stations, the presence of tumors in the surgical margins, various treatments will be applied to completely get rid of the disease or to prolong the recurrence period as much as possible, or to suppress the disease, with additional treatments at the appropriate time. Recently, the increase in the diversity of these treatments has strengthened the clinician's hand against the disease and has created the chance to give the right treatment at the right time.
However, in some advanced cases, the chance of cure (complete recovery) of patients is lost. In locally advanced and metastatically advanced stages of prostate cancer, they may consult a physician. In these stages, they can be diagnosed as spreading to lymph stations, spreading to bones, especially spinal bones, or spreading to other organs in the body (such as lung, liver, brain). Prostate cancer In cases where prostate cancer has spread to bones and other internal organs, many different types of treatment have been used in recent years. Advances in hormone therapies, oncological treatments, and nuclear medicine are helping to prolong cancer-related and overall survival of patients.
Increasing public awareness, the encouragement of patients to screening campaigns, and the increase in diagnosis rates in the early stages have increased the rates of curative (complete recovery) treatment of prostate cancer. It is hoped that the discovery of prostate cancer-specific MRI and the widespread use of targeted biopsies will further increase the rate of early diagnosis and decrease the rate of detection in the fatal stage.